Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021
January 10, 2022 at 09:16 am EST
Share
Ekso Bionics Holdings, Inc. provided revenue guidance for the fourth quarter and full year ended December 31, 2021. Total revenue for the fourth quarter of 2021 is an estimated range of $3.9 million to $4.1 million, reflecting year-over-year growth of 77% at the midpoint of the range, compared to total revenue of $2.3 million in the fourth quarter of 2020.
Total revenue for fiscal year 2021 is an estimated range of $11.1 million to $11.3 million, compared to $8.9 million in 2020. This reflects estimated year-over-year growth of 26% at the midpoint of the range.
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.